Walsh M - Search Results

1

Glucocorticoid Minimization in Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis: An International Survey of Clinicians.

Massicotte-Azarniouch D, Canney M, Karnabi P, Merkel PA, Jones RB, Pepper RJ, Salama AD, Derebail VK, Milman N, Junek M, Pagnoux C, Jayne DRW, Walsh M. Massicotte-Azarniouch D, et al. Among authors: walsh m. Kidney Med. 2024 Jun 14;6(8):100858. doi: 10.1016/j.xkme.2024.100858. eCollection 2024 Aug. Kidney Med. 2024. PMID: 39131917 Free PMC article.

2

Surrogate end points in clinical trials: the case of anti-neutrophil cytoplasm antibody-associated vasculitis.

Walsh M, Tonelli M, Jayne D, Manns B. Walsh M, et al. J Nephrol. 2007 Mar-Apr;20(2):119-29. J Nephrol. 2007. PMID: 17514615 Review. No abstract available.

3

Rituximab in the treatment of anti-neutrophil cytoplasm antibody associated vasculitis and systemic lupus erythematosus: past, present and future.

Walsh M, Jayne D. Walsh M, et al. Kidney Int. 2007 Sep;72(6):676-82. doi: 10.1038/sj.ki.5002395. Epub 2007 Jul 4. Kidney Int. 2007. PMID: 17609693 Free article. Review.

4

Mycophenolate mofetil for induction therapy of lupus nephritis: a systematic review and meta-analysis.

Walsh M, James M, Jayne D, Tonelli M, Manns BJ, Hemmelgarn BR. Walsh M, et al. Clin J Am Soc Nephrol. 2007 Sep;2(5):968-75. doi: 10.2215/CJN.01200307. Epub 2007 Aug 8. Clin J Am Soc Nephrol. 2007. PMID: 17702723 Review.

5

Long-term follow-up of relapsing/refractory anti-neutrophil cytoplasm antibody associated vasculitis treated with the lymphocyte depleting antibody alemtuzumab (CAMPATH-1H).

Walsh M, Chaudhry A, Jayne D. Walsh M, et al. Ann Rheum Dis. 2008 Sep;67(9):1322-7. doi: 10.1136/ard.2007.081661. Epub 2007 Nov 29. Ann Rheum Dis. 2008. PMID: 18055469 Clinical Trial.

6

Targeting the B cell in vasculitis.

Walsh M, Jayne D. Walsh M, et al. Pediatr Nephrol. 2009 Jul;24(7):1267-75. doi: 10.1007/s00467-008-1010-z. Epub 2008 Oct 18. Pediatr Nephrol. 2009. PMID: 18931860 Review.

7

What is the value of mycophenolate mofetil as induction and maintenance therapy in lupus nephritis?

Jones RB, Walsh M, Smith KG. Jones RB, et al. Among authors: walsh m. Curr Opin Rheumatol. 2009 May;21(3):256-61. doi: 10.1097/bor.0b013e32832a0698. Curr Opin Rheumatol. 2009. PMID: 19399995 Review.

8

Progress towards a core set of outcome measures in small-vessel vasculitis. Report from OMERACT 9.

Merkel PA, Herlyn K, Mahr AD, Neogi T, Seo P, Walsh M, Boers M, Luqmani R. Merkel PA, et al. Among authors: walsh m. J Rheumatol. 2009 Oct;36(10):2362-8. doi: 10.3899/jrheum.090373. J Rheumatol. 2009. PMID: 19820226 Free PMC article.

9

Practice pattern variation in oral glucocorticoid therapy after the induction of response in proliferative lupus nephritis.

Walsh M, Jayne D, Moist L, Tonelli M, Pannu N, Manns B. Walsh M, et al. Lupus. 2010 Apr;19(5):628-33. doi: 10.1177/0961203309356292. Epub 2010 Jan 12. Lupus. 2010. PMID: 20068016

10

Effects of duration of glucocorticoid therapy on relapse rate in antineutrophil cytoplasmic antibody-associated vasculitis: A meta-analysis.

Walsh M, Merkel PA, Mahr A, Jayne D. Walsh M, et al. Arthritis Care Res (Hoboken). 2010 Aug;62(8):1166-73. doi: 10.1002/acr.20176. Arthritis Care Res (Hoboken). 2010. PMID: 20235186 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

4,750 results

Search Page

Filters